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1. Introduction 
Endometrial cancer is the fourth most common cancer and the most common gynecological 
cancer diagnosed in the women in the United States.  The lifetime risk of developing 
endometrial cancer is 2.58% in US women. The American Cancer Society estimates 
approximately 47,000 new cases and 8,120 deaths due to endometrial cancer in 2011 (Siegel 
et al. 2011). There does appear to be a significant difference in prognosis based on race. The 
incidence of endometrial cancer is higher in white women compared to the black women 
(age adjusted incidence rate: 24.8 vs. 20.9 per 100,000 women), but the death rate from 
endometrial cancer in the black women is almost two times that of the white women (age 
adjusted death rate: 3.9 vs. 7.2 per 100,000 women) (Howlader N). Furthermore,  the 
incidence and the death rate have remained stable in the white women; although it has been 
rising steadily in the black women (by 1.7% per year and 0.8% per year, respectively) 
(Howlader N).  
The management strategies in endometrial cancer have evolved dramatically in the past 
two decades. Despite the advances in the treatment of endometrial cancer; the death rate 
from endometrial cancer remains high. Clearly, more effective treatment strategies are 
needed.  
2. Histological classification 
Endometrial cancer can be divided into two histologic subtypes: Type I and Type II. Type I 
endometrial cancers account for the majority of uterine cancer cases and occur more 
commonly in association with overexposure to estrogen. They are of endometrioid 
histology, diagnosed in early stages, and are commonly associated with K-ras, PTEN, 
and/or mismatch repair gene mutations. They are also associated with obesity. Type II 
endometrial cancers, on the other hand, are typically of aggressive non endometrioid 
histology and are therefore more commonly diagnosed in advanced stages. They often 
develop in a background of atrophic endometrium (Bokhman 1983) and have a greater 
probability of having p53 mutations and/or HER2/neu over expression (Prat et al. 2007). 
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3. Management of endometrial cancer 
The primary treatment of endometrial cancer is surgical. Following tissue diagnosis, most 
patients are offered surgical staging. Routine preoperative work-up includes complete 
blood count, serum electrolytes/ creatinine, liver function tests, urinalysis, and a CXR. 
Further evaluation with CT/MRI/PET-CT (with or without CA-125) may be performed, if 
extrauterine disease is suspected on initial assessment. In patients with suspected  
cervical involvement, MRI or cervical biopsy may be helpful to confirm the diagnosis 
(Akin et al. 2007). 
3.1 Surgical staging and related issues 
In 1988 the FIGO staging committee replaced the clinical staging system for endometrial 
cancer with a surgical staging system. This transition from clinical to surgical staging was 
mainly due to the seminal findings of a large gynecologic oncology group trial (GOG 33), 
which evaluated the surgical-pathologic patterns in apparent early stage endometrial cancer 
with particular emphasis on pelvic and para-aortic lymph node involvement (Creasman et 
al. 1987). A significant number (25%) of patients with clinical stage I in this study were 
found to have extrauterine disease upon comprehensive surgical staging.  
The 1988 FIGO staging system was recently modified (Pecorelli et al. 2009). These two 
staging criteria are shown in Tables 1 and 2 respectively. 
 
Stage IA G123  Tumor limited to the endometrium 
Stage IB G123  Invasion to less than half of the myometrium 
Stage IC G123  Invasion equal to or more than half of the myometrium 
Stage IIA G123  Endocervical glandular involvement only 
Stage IIB G123  Cervical stromal invasion 
Stage IIIA G123  
Tumor invades serosa and/or adnexa and/or positive peritoneal 
cytology 
Stage IIIB G123  Vaginal metastasis 
Stage IIIC G123  Metastasis to pelvic and/or para-aortic lymph nodes 
Stage IVA G123  Tumor invasion of bladder and/or bowel mucosa 
Stage IVB G123  
Distant metastasis including intra-abdominal metastasis and/or 
inguinal lymph nodes 
Table 1. 1988 FIGO Surgical Staging for Endometrial Cancer. 
 
Stage IA G123  Invasion to less than half of the myometrium 
Stage IB G123  Invasion equal to or more than half of the myometrium 
Stage II G123  Cervical stromal invasion 
Stage IIIA G123  Tumor invades serosa and/or adnexa 
Stage IIIB G123  Vaginal metastasis 
Stage IIIC1 G123  Metastasis to pelvic lymph nodes 
Stage IIIC2 G123  Metastasis to para-aortic lymph nodes 
Stage IVA G123  Tumor invasion of bladder and/or bowel mucosa 
Stage IVB G123  
Distant metastasis including intra-abdominal metastasis and/or 
inguinal lymph nodes 
Table 2. 2009 FIGO Surgical Staging for Endometrial Cancer. 
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The current standard surgical staging procedure includes total abdominal hysterectomy, 
bilateral salpingo-oophorectomy, pelvic and para-aortic lymphadenectomy, peritoneal 
washings for cytology, and meticulous exploration of the abdomen and pelvis with biopsy 
of any suspicious lesions (NCCN guidelines for uterine neoplams, V.2.2011) (NCCN Clinical 
Practice Guidelines in Oncology (NCCN Guidelines™) for Uterine Neoplasms V.2.2011. © 
2011 National Comprehensive Cancer Network). This procedure has been shown feasible by 
laparoscopy. In LAP-2 trial; the pelvic and para-aortic lymph nodes were obtained in 96% 
patients undergoing laparotomy compared to 92% of those who had laparoscopy (p<0.001). 
The detection rate of advanced stage was also comparable between the groups (17% vs. 17%, 
p=0.841) (Walker et al. 2009). 
GOG 33 identified that depth of myometrial invasion, and tumor grade were predictive of 
lymph node metastasis (Creasman et al. 1987) and that all were predictive of recurrence. The 
preoperative and intra-operative evaluation of these high-risk features is often inaccurate, 
and surgical staging is therefore recommended in most patients diagnosed with endometrial 
cancer (NCCN guidelines for uterine neoplasms, V.2.2011). 
The preoperative tumor grade was upgraded on final pathology in approximately 18% 
patients in different studies (Goudge et al. 2004) (Ben-Shachar et al. 2005). Neither imaging 
nor frozen section is very accurate for assessing the depth of myometrial invasion. In a 
recent study by Case et al, concordance between frozen and final pathology was noted only 
in 67% patients for depth of myometrial invasion and 58% patients for tumor grade (Case et 
al. 2006). The sensitivity of MRI has similarly been found to be only 54%-75% in this regard 
(Hricak et al. 1991; Nakao et al. 2006). 
The use of imaging (CT, MRI, and PET-CT) has been evaluated for the pre-operative 
assessment of lymph node metastasis in endometrial cancer. Park et al showed that the 
sensitivity and specificity of MRI and PET-CT was only modest (46% and 88%; and 69% 
and 90%, respectively) (Park et al. 2008). Palpation of lymph nodes is also not reliable, 
with a false negative rate of over 35% in some studies (Girardi et al. 1993; Arango et al. 
2000). Intra-operative frozen section evaluation was found to miss nearly 2/3rds of 
endometrial cancer patients with positive lymph nodes, in a recent study (Pristauz et al. 
2009).  
Several retrospective studies have shown an improvement in survival following pelvic and 
para-aortic lymphadenectomy (Kilgore et al. 1995; Mohan et al. 1998; Trimble et al. 1998; 
Cragun et al. 2005; Chan et al. 2006). In contrast, no survival benefit could be demonstrated 
in either of the two recent prospective randomized controlled trials (Kitchener et al. 2009; 
Panici et al. 2008). The ASTEC trial recruited 1,408 women with early stage endometrial 
cancer from 85 centers across four countries (U.K., Poland, New Zealand, and South Africa) 
(Kitchener et al. 2009).  These women were randomized to undergo surgery either with or 
without lymphadenectomy. To control for postsurgical treatment, women with intermediate 
or high risk of recurrence were randomized into the ASTEC radiotherapy trial. No survival 
benefit was observed from pelvic lymphadenectomy in this trial. The 5-year overall survival 
was 81% in the surgery only group and 80% in the surgery plus lymphadenectomy group 
(HR: 1.04, CI: 0.74-1.45, p=0.83). The corresponding 5-year recurrence free survival was 79% 
and 73%, respectively (HR: 1.25, CI: 0.93-1.66, p=0.14). In another randomized study from 
Italy, 514 patients with preoperative FIGO stage I endometrial carcinoma were evaluated 
(Panici et al. 2008). At a median follow-up of 49 months, the rates of disease free survival 
www.intechopen.com
 Cancer of the Uterine Endometrium – Advances and Controversies 
 
126 
(81.0% vs. 81.7%, HR: 1.20, CI: 0.75-1.91) and overall survival (85.9% vs. 90.0%; HR: 1.16, CI: 
0.67-2.02) were not significantly different between the lymphadenectomy and the no-
lymphadenectomy arms. Although, these trials have been criticized for various 
shortcomings (Amant et al. 2009; Uccella et al. 2009; Uccella et al. 2009); they constitute level 
one evidence and indicate that lymphadenectomy by itself does not provide survival 
advantage in endometrial cancer. 
The morbidity associated with surgical staging has been reported in several studies 
(Moore et al. 1989; Larson and Johnson 1993; Franchi et al. 2001). In a study of 168 patients 
with endometrial cancer; the short term complications after complete surgical staging 
included fever (31.5%), surgical site infection (4.7%), embolic events (1.3%), and death 
(0.7%). The late complications in this series were leg edema (0.7%), intestinal obstruction 
(0.7%), and lymphocysts (1.3%) (Larson et al. 1993). In another study by Cragun et al, 
adverse events were noted in 18% patients. The most common complications were illeus 
(2.6%), deep venous thrombosis (2.6%), lymphocysts (2.4%), and small bowel obstruction 
(1.8%) (Cragun et al. 2005). The postoperative morbidity after  surgical staging was 
significantly less in patients undergoing laparoscopy compared to those who had the 
procedure performed via  laparotomy (14% vs. 21%, p<0.001) in the LAP-2 trial (Walker et 
al. 2009). To further limit the morbidity associated with complete lymph node dissection; 
sentinel lymph node detection is being evaluated in endometrial cancer (Gien et al. 2005; 
Delaloye et al. 2007; Frumovitz et al. 2007). Though controversial worldwide, FIGO 
staging remains the standard at this time as it allows for more accurate post surgical 
treatment. 
3.2 Treatment after surgical staging 
Treatment after initial staging depends on the final stage assigned after regarding 
different surgical-pathologic risk factors. It is discussed here under three broad headings: 
treatment of stage I endometrial cancer; treatment of endometrial cancer with cervical 
involvement (stage II); and treatment of advanced stage endometrial cancer(stages III and 
IV) (Table 3). 
3.2.1 Treatment of stage I endometrial cancer 
3.2.1.1 Low-risk patients 
Patients with no myometrial invasion and grade 1/2 disease have particularly low risk of 
recurrence (2-10%) (Creasman et al. 1987). Neither pelvic external beam radiotherapy nor 
vaginal brachytherapy is recommended for these patients. In a recent study, no vaginal 
recurrences were reported in these patients after surgery alone (Straughn et al. 2002). 
3.2.1.2 Intermediate risk 
Intermediate risk endometrial cancer is divided into low-intermediate risk and high-
intermediate risk disease. Low-intermediate risk group includes patients with no 
myometrial invasion and grade 3 disease; patients with less than 50% myometrial invasion 
and grade 1/2 disease. High-intermediate risk group includes patients with less than 50% 
myometrial invasion and grade 3 disease; patients with myometrial invasion ≥50% and 
grade 1/2 disease; and patients with stage IIA disease and grade 1/2 disease. 
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1: All staging is based on updated 2009 FIGO staging. 
2: Adapted with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN 
Guidelines™) for Uterine Neoplasms V.2.2011. © 2011 National Comprehensive Cancer Network, Inc. 
All rights reserved. The NCCN Guidelines™ and illustrations herein may not be reproduced in any 
form for any purpose without the express written permission of the NCCN. To view the most recent 
and complete version of the NCCN Guidelines, go online to NCCN.org. NATIONAL 
COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES™, and all other NCCN 
Content are trademarks owned by the National Comprehensive Cancer Network, Inc. 
Table 3. NCCN Guidelines for Adjuvant Treatment in Endometrial Cancer. 
Patients in intermediate risk group have been the subjects of different randomized 
controlled trials (Table 4). The Norwegian trial led by Aalders et al recruited 540 stage I 
patients between 1968-1974 (Aalders et al. 1980). All patients underwent surgery and 
subsequently received vaginal brachytherapy at the dose of 60 Gy. Patients were then 
randomized to receive either external beam radiotherapy (EBRT) or no further treatment 
(NFT). The vaginal and pelvic recurrence rate was higher in the observation arm compared 
to the radiotherapy arm (7% vs. 2%, p=0.01). Interestingly, the distant failure rate was higher 
in the radiotherapy group than the control group (10% vs. 5%, p=0.05). The 5-year overall 
survival was not different between the groups. A distinct survival advantage was observed 
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on subgroup analysis among  patients with grade 3 tumor and deep myometrial invasion 
who had received RT (Aalders et al. 1980). 
PORTEC-1 included stage I endometrial cancer patients with either: grade I disease and 
deep myometrial invasion (≥50%); grade II disease with any myoinvasion; or grade III 
disease with superficial (<50%) myometrial invasion (Creutzberg et al. 2000). A total of 715 
patients were enrolled. All patients underwent a total abdominal hysterectomy and bilateral 
salpingo-oophorectomy without lymph node dissection. Subsequently, these patients were 
randomized to external beam radiotherapy or no further treatment. The loco-regional 
recurrence rate was significantly lower in the EBRT arm compared to the NFT arm (4% vs. 
14%, p<0.001). The distant recurrence rate, the 5-year overall survival rate, and the 
endometrial cancer related death rate were however comparable (p≥0.05). Treatment related 
complications were more common in the radiotherapy group compared to the control group 
(25% vs. 6%, p<0.001).  Scholten et al published a 10-year follow-up of PORTEC-1, which 
excluded cases downgraded after central pathology review (Scholten et al. 2005). Similar to 
the original study, the 10-year loco-regional relapse rate was significantly higher in the no 
further treatment group compared to the RT group (14% vs. 5%, p>0.001). Radiation was 
particularly effective in patients with two out of the following three high-risk features (age 
>60 years, > 50% myometrial invasion, and grade III)--loco-regional recurrence rate 4% in 
the RT group vs. 23% in the control group. Most loco-regional recurrences however were 
isolated vaginal recurrences, with higher salvage rate in control group versus the RT group 
(70% vs. 38%). 
The Gynecologic Oncology Group also evaluated the role of adjuvant pelvic radiotherapy in 
patients with early stage endometrial cancer (GOG 99) (Keys et al. 2004). This trial included 
patients with stage IB, IC, and stage II (occult) disease. Patients with clear cell and papillary 
serous endometrial cancers were excluded. All patients were required to undergo a 
complete surgical staging procedure. Afterwards, patients were randomized to either no 
further treatment or external beam radiation. Based on the following risk factors: age, 
lymphovascular space invasion, grade III tumors, and outer third myometrial invasion; a 
high intermediate risk group was defined  including patients aged  ≥70 years with ≥1 risk 
factor; 50-70 years with  ≥ 2 risk factors; or <50 years with all three risk factors. All other 
patients were considered low-intermediate risk. The median follow up was 69 months. The 
two year cumulative incidence of recurrence was 12% in the no additional treatment arm 
and 3% in the RT arm (relative hazard=0.42, p=0.007). Majority of the difference between the 
two groups could be explained on the basis of disparity in the occurrence of vaginal 
recurrences (13 in the NFT arm and 2 in the RT arm). The overall survival was not 
significantly different between the RT and the NFT groups (p=0.56). On subgroup analysis, 
RT resulted in statistically significant improvement in the incidence of recurrence in the 
high intermediate risk group (2 year CIR: 6% VS. 26%; relative hazard 0.42, 90% CI: 0.21-
0.83), but not in the low-intermediate risk group (2 year CIR: 2% VS. 6%; relative hazard: 
0.46, 90% CI: 0.19-1.11). However, patients in the RT group experienced more frequent and 
more severe toxicities, and the difference was particularly significant for hematologic, 
gastrointestinal, genitourinary, and cutaneous toxicities.  
ASTEC/EN.5 trial enrolled 905 women between 1996-2005 with node negative early stage 
endometrial cancer (stages I-IIA) and intermediate or high risk features (IA grade 3, IB all 
grades, papillary serous or clear cell histology all stages and grades) (Blake et al. 2009). After 
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surgery, brachytherapy was allowed to all patients according to the local policy. Patients 
were then randomized to either EBRT or observation. There was no difference between 
groups in regards to either overall survival (5-year OS: 84% in both groups; HR 1.05 CI: 0.75-
1.48, p=0.77) or recurrence free survival (84.7% NFT vs. 85.3% EBRT; HR: 0.92 CI: 0.66-1.31). 
The 5-year cumulative incidence of isolated vaginal or pelvic recurrence was 6.1% in the 
NFT arm and 3.2% in the EBRT arm (HR 0.46 CI: 0.24-0.89, p=0.02). Both acute (57% vs. 27%) 
and late toxicity (61% vs. 45%) was significantly more in the EBRT group compared to the 
observation group. 
Based on the results of these trials, it appears that radiotherapy decreases the incidence of 
loco-regional recurrence but does not improve survival. The reduction of loco-regional 
recurrences is mainly due to a decrease in the incidence of vaginal recurrences which 
accounted for almost 75% of all locoregional recurrences in the control arm. Given the 
adverse effects noted with radiation, a randomized PORTEC-2 trial was opened to 
investigate if vaginal brachytherapy would be as effective as EBRT (Nout et al. 2010).  
Patients at high-intermediate risk for recurrence were eligible for enrollment (age >60 years 
and IC grade 1/2 disease or stage IB grade 3 disease; stage IIA any age (apart from grade 3 
with >50% myometrial invasion). All patients underwent a total abdominal hysterectomy 
and bilateral salpingo-oophorectomy without lymphadenecetomy. Subsequently, patients 
were randomized to receive either pelvic RT or vaginal brachytherapy. The 5-year vaginal 
recurrence rate was 1.8% in the vaginal brachytherapy group (VBT) and 1.6% in the EBRT 
group (HR=0.78 CI: 0.17-3.49; p=0.74). Although, pelvic recurrence rate was higher in the 
VBT arm (3.8% vs. 0.5%; p=0.02); there was no difference between groups regarding the 
incidence of either locoregional recurrence (EBRT: 2.1% vs. VBT: 5.1%; p=0.17), distant 
recurrence (EBRT: 5.7% vs. VBT: 8.3%; p=0.46), or survival (5-year overall survival: 79.6% in 
EBRT vs. 84.8% in VBT; p=0.57). The gastrointestinal side effects were however significantly 
more common in the EBRT group compared to the VBT group (53.8% v12.6%, respectively) 
with resultant poorer quality of life (Nout et al. 2009). 
 
 
1: Statistically significant difference; 2:  4-yr OS 
LND: Lymph Node Dissection; LRR: Locoregional Recurrence Rate; DRR: Distant Recurrence Rate 
Sx: Surgery; VBT: Vaginal Brachytherapy; EBRT: External Beam Radiotherapy  
GOG: Gynecologic Oncology Group 
Table 4. Randomized Controlled Trials of Adjuvant Radiotherapy in Early Stage 
Endometrial Cancer. 
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These data suggest that vaginal brachytherapy could be used as effectively as external beam 
RT to optimize local control in patients deemed to be at high-intermediate risk, and with less 
morbidity and better quality of life.  
3.2.1.3 High risk patients  
High risk endometrial cancer includes patients with 1988 FIGO stage IC with grade 3 
disease and/or lymphovascular space invasion; 1988 FIGO stage IIA with grade 3 disease, 
deep myometrial invasion, and/or lymphovascular space invasion; stages IIB, III and IV; 
clear cell or papillary serous histologies. Creutzberg et al compared 104 patients with stage 
IC grade 3 endometrial cancer against the PORTEC patients who received RT (Creutzberg et 
al. 2004).  The locoregional recurrence rate was 1-3% among the PORTEC patients, and 14% 
for stage IC grade 3 patients. The 5-year distant metastasis rates were 3-8% for grade 1/2 
patients, 20% for stage IB grade III patients, and 31% for stage IC grade III patients. The 
high-risk patients remain at significant risk for distant failure despite EBRT. In an attempt to 
improve distant failure rate and survival in these patients, the use of adjuvant 
chemotherapy has been explored in several clinical trials (Table 5). The results of most of 
these trials have been negative with the exception of two trials (Randall et al. 2006 and 
Hogberg et al. 2010). 
 
 
1: Statistically significant difference. 
Sx: Surgery; XRT: Radiotherapy; A: Doxorubicin; CAP: Cyclophosphamide + Doxorubicin + Cisplatin; 
CT: Chemotherapy 
GOG: Gynecologic Oncology Group; JGOG: Japanese Gynecologic Oncology Group; NSGO-EORTC: 
The Nordic Society of Gynecologic Oncology- European Organization for Research and Treatment of 
Cancer; MaNGO: Mario Negri Institute. 
Table 5. Randomized Controlled Trials of Adjuvant Chemotherapy in Early Stage 
Endometrial Cancer. 
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Morrow et al included patients diagnosed with stages IC-IIIC (Morrow et al. 1990). All 
patients underwent a complete staging followed by the administration of pelvic RT. Patients 
were then randomized to either doxorubicin (45 mg/m2) or no further treatment. There was 
no significant difference with regards to either overall survival or progression free survival 
between the chemotherapy group and the observation group. There was a trend towards 
fewer extrapelvic recurrences in the doxorubicin arm compared to the control arm (16.3% 
vs. 22.5%).  
In an Italian trial, patients were randomized to either chemotherapy with 
cyclophosphamide (600 mg/m2), doxorubicin (45 mg/m2 ), and cisplatin (50 mg/m2) 
[CAP] or radiation treatment after the initial staging (Maggi et al. 2006). Only one third of 
the patients in this trial were stage I/II, remaining 2/3 had stage III disease. There was no 
difference between the CT arm and the RT arm with regards to either overall survival (5year 
OS: 66% vs. 69%; p=0.78) or progression free survival (5-year PFS: 63% vs. 63%; p=0.45). 
There were more local recurrences in the CT group compared to the RT group (11% vs. 7%); 
but distant recurrences were higher in the RT group than the CT group (21% vs. 16%).  
In a similar study design; Susumu et al evaluated patients with stages IC-IIIC with > 50% 
myometrial invasion and no residual tumor after surgery (Susumu et al. 2008). Patients 
received either pelvic RT (45-50 Gy) or chemotherapy with cyclyophosphamide (333 mg/m2), 
doxorubicin (40 mg/m2), and cisplatin (50 mg/m2). Patients were divided into low-
intermediate risk group (IC plus age <70 years plus grade I/II) and high-intermediate risk 
group (IC plus age >70 years plus grade III or stage II/IIIA with > 50% myometrial invasion). 
The 5-year progression free survival for low-intermediate risk patients was 94.5% in the RT 
group and 87.6% in the CT group (p=0.11). The corresponding 5-year overall survival rates 
were 95.1% and 90.8%, respectively (p=0.28). The survival was however significantly better in 
the CT group compared to the RT group among the high-intermediate risk patients (5-year 
PFS: 83.8% vs. 66.2%, p=0.024; 5-year OS: 89.7% vs. 73.6%, p=0.006). The overall incidence of 
G3/G4 complications was 1.6% in the RT group and 4.7% in the CT group. 
Kuoppala et al  randomized high-risk patients after surgery to either radiotherapy alone or 
radiation plus chemotherapy with cisplatin(50 mg/m2), doxorubicin(60 mg/m2 ), and 
cyclophosphamide (500 mg/m2) (Kuoppala et al. 2008). Adjuvant chemotherapy failed to 
improve overall survival or the recurrence rate in their study [ 5-year disease specific 
survival: 84.7% RT vs. 82.1% RT +CT, p=0.148;  median disease free survival: 18 months for 
RT vs. 25 months for RT+ CT, p=0.134).  
The Nordic society for gynecologic oncology 9501/ European Organization for Research 
and Treatment of Cancer Group 55991 and MaNGO/ILIADE-III trial compared radiation 
alone to radiation followed by CT (Hogberg et al. 2010). The combination of radiation and 
chemotherapy was associated with a superior progression free survival (HR: 0.63, CI: 0.44-
0.89; p=0.009) and cancer specific survival (HR: 0.55, CI: 0.35-0.88; p=0.01) compared to the 
radiation only arm. Recently, the Cochrane review group led by Johnson et al reported 
(presented in abstract form at the 2010 annual meeting of the International Gynecological 
Cancer Society) data from 7 randomized trials and 1,919 women showing a survival 
advantage in favor of adjuvant chemotherapy (RR:  0.85 CI: 0.75-0.96) (Lai et al. 2011). 
While, there is little doubt as to the usefulness of chemotherapy in the treatment of high-risk 
patients; its role in the treatment of these patients will be further clarified with the results of 
PORTEC-3 trial (comparing EBRT+CT vs. EBRT alone). It is debatable whether patients 
receiving adjuvant radiotherapy should receive pelvic RT or vaginal brachytherapy alone. 
The exclusion of RT in these patients has been shown to increase the risk of pelvic failure in 
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some studies (Mundt et al. 2001; Klopp et al. 2009). GOG 249 is currently evaluating 
outcomes in high-intermediate risk and high risk endometrial cancer patients treated with 3 
cycles of carboplatin/taxol followed by either VBT or EBRT. 
The role of hormone therapy in early stage endometrial cancer has been studied in different 
randomized trials (Table 6). Only patients with stage I endometrial cancer were included in 
four trials (Lewis et al. 1974; Malkasian and Bures 1978; Macdonald et al. 1988; De Palo et al. 
1993). Other trials also included patients with more advanced disease (COSA-NZ-UK 
Endometrial Cancer Study Group ; Vergote et al. 1989; Urbanski et al. 1993). A meta-analysis 
of four of these trials was recently reported by Martin-Hirsch et al. There was no significant 
difference in the risk of death between patients who received progestogen compared to 
those who did not receive progestogen (RR: 1.00, CI: 0.85-1.18)(Martin-Hirsch et al. 2011). 
Although, the risk of relapse was lower in patients receiving progestogen compared to those 
who did not receive progestogen (RR: 0.71, CI: 0.52-0.97) (Urbanski et al. 1993); this effect 
was not reproduced in another trial (RR 1.34, CI: 0.79-2.27) (De Palo et al. 1993). The authors 
concluded that there is no evidence to support the routine use of progestogens in the 
primary treatment of endometrial cancer.  
 
 
1: Favors progestogen. 
Table 6. Randomized Controlled Trials of Adjuvant Hormonal Therapy in Early Stage 
Endometrial Cancer. 
3.2.2 Treatment of endometrial cancer with cervical involvement 
In the past, one of the most commonly employed procedure  for the treatment of these 
patients was preoperative RT followed by total abdominal hysterectomy. The 5-year 
actuarial survival rate reported among patients treated with pre or postoperative radiation 
therapy has been reported to range from 57% to 85% and 52% to 87%, respectively (Menczer 
2005). Calais et al performed a retrospective comparison of outcomes among 184 patients 
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who received vaginal brachytherapy before or after radical hysterectomy (Calais et al. 1990). 
There was no significant difference in survival between patients treated with either 
preoperative or postoperative radiation therapy (87% and 91%, respectively). Similarly, the 
incidence of local recurrence (13% vs. 9%) and distant recurrence (12% and 9%) was also 
comparable between the two groups. Although, not statistically significant, a trend towards 
more late complications was observed in patients treated with preoperative radiation (14% 
vs. 7.9%). Similar results have been reported by others (Lanciano et al. 1990). Additionally, 
preoperative RT can confound the pathological determination of grade, depth of myometrial 
invasion, and pelvic lymph node involvement. 
The role of radical hysterectomy in endometrial cancer with cervical involvement has been 
investigated by several authors. A series by Sartori et al included 203 patients with stage II 
endometrial cancer (Sartori et al. 2001). Of these; 66% underwent a simple TAH, whereas 
RH was performed in the remaining 34% patients. The 5-year survival rates were 
significantly better in the RH group compared to the TAH group (94% vs. 79%, p<0.05). The 
local and distant recurrences were also fewer in the RH group. Cornelison et al also 
demonstrated a superior survival among stage II endometrial cancer patients treated with 
RH compared to TAH (surgery only group: 93% vs. 84%, p<0.05; surgery plus radiation 
group: 88% vs. 82.7%, p<0.05)(Cornelison et al. 1999). 
The schema for risk-stratification for stage II patients and results of clinical trials have been 
discussed elsewhere in this chapter. The NCCN recommendations for management of this 
group of patients are as shown in figure 1. Although, both pelvic RT and brachytherapy are 
recommended; observation or vaginal brachytherapy is also an option for stage II patients 
who have undergone a RH with negative surgical margins and no evidence of extrauterine 
disease (NCCN guidelines for uterine neoplams, V.2.2011). In a small study by Ng et al, no 
recurrences were observed in stage II patients undergoing extended surgical staging 
followed by vaginal vault brachytherapy (Ng et al. 2001). 
 
 
Adapted with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN 
Guidelines™) for Uterine Neoplasms V.2.2011. © 2011 National Comprehensive Cancer Network, Inc. 
All rights reserved. 
The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose 
without the express written permission of the NCCN. To view the most recent and complete version of 
the NCCN Guidelines, go online to NCCN.org. 
NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES™, and all 
other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc. 
Fig. 1. Schematic representation of primary management of endometrial cancer with cervical 
involvement.   
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3.2.3 Treatment of advanced stage endometrial carcinoma (stages III and IV) 
Although, most endometrial cancers are diagnosed in early stages due to symptoms; those 
who are diagnosed in advanced stages do poorly on available treatments. Generally, a 
multimodality approach involving surgery ± radiation ± chemotherapy ± hormonal agents 
is required. NCCN guidelines for the management of these patients are shown in Figure 2.  
 
 
Adapted with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN 
Guidelines™) for Uterine Neoplasms V.2.2011. © 2011 National Comprehensive Cancer Network, Inc. 
All rights reserved. 
The NCCN Guidelines™ and illustrations herein may not be reproduced in any form for any purpose 
without the express written permission of the NCCN. To view the most recent and complete version of 
the NCCN Guidelines, go online to NCCN.org. 
NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES™, and all 
other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc. 
Fig. 2. Schematic representation of primary management of endometrial cancer with 
extrauterine disease.  
3.2.3.1 Role of cytoreductive surgery 
The role of cytoreductive surgery in patients diagnosed with advanced stage endometrial 
cancer is debatable. Goff et al showed that survival was significantly better in patients that 
were cytoreduced (18 months) compared to those that did not undergo surgery (8 months) 
(Goff et al. 1994). In another study, Chi et al compared the outcomes among those stage IV 
endometrial cancer patients that underwent either optimal cytoreduction  (residual disease 
≤2 cm), suboptimal cytoreduction (gross residual disease >2cm), or no cytoreduction (Chi et 
al. 1997). The median survival recorded for patients in these groups was 31 months , 13 
months, and 3 months, respectively (p<0.01). Only the extent of cytoreduction was a 
significant predictor of survival on multivariate analysis. Similar findings have been 
reported by other investigators (Bristow et al. 2000; Ayhan et al. 2002). Although, data from 
these small retrospective studies appear encouraging, it is important to note that there has 
been  no randomized trial to date to validate this beneficial effect. 
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3.2.3.2 Role of radiotherapy 
Pelvic radiotherapy with or without vaginal brachytherapy has been used to prevent local 
and/or lymph node metastasis in patients with advanced stage endometrial cancer. In a 
study by Mariani et al,  the incidence of pelvic side wall recurrences  at 5 years was 57% 
among those node positive stage III/IV endometrial cancer patients that underwent  
inadequate node dissection and/or no radiotherapy compared to 10% for those receiving 
both adequate lymphadenectomy and postoperative radiotherapy (p<0.001)(Mariani et al. 
2006). While the 5-year para-aortic failure rate was 34% among patients undergoing para-
aortic lymphadenectomy and no adjuvant radiation; there were no failures among those 11 
patients who received both para-aortic lymphadenectomy and para-aortic radiation. 
Similarly, in a study, by Mundt et al, there was a trend towards improved local failure rate 
among those stage IIIC endometrial cancer patients who received vaginal brachytherapy 
compared to those who did not (vaginal recurrence: 0/10 vs. 4/20; p=0.12)(Mundt et al. 
2001).   
Due to the risk of abdominal recurrence in advanced stage endometrial cancer and/or high-
risk histologies; the use of whole abdominal radiation has been proposed. Smith et al 
reported a 3-year estimated progression free survival of 79% and overall survival of 89% in 
22 patients with stage III/IV adenocarcinoma using postoperative whole abdominal 
radiation(Smith et al. 2000). All four failures in these patients were extra-abdominal. The 3 
year actuarial major complication rate was 7% in their series, and there were no treatment 
related deaths. In another report by Gibbons et al; the 7-year disease specific survival after 
WAI was 57.8% for stage III and 25.0% for stage IV disease (p=0.006)(Gibbons et al. 1991). 
Although, acute toxicity was common, the complications were generally mild.  
In the GOG study, the 3-year recurrence free survival was 29% and overall survival was 31% 
in patients with endometrial adenocarcinoma (Sutton et al. 2005). The corresponding rates in 
papillary serous/clear cell carcinoma were 27% and 35%, respectively. The incidence of 
different types of severe toxicities was as follows:  myelosuppression (12.6%), 
gastrointestinal toxicity (15%), and hepatic toxicity (2.2%). Although these results look 
promising, GOG 122 emphatically established the superiority of chemotherapy over whole 
abdominal radiation in the treatment of patients with advanced stage endometrial 
cancer(Randall et al. 2006). The progression free survival and overall survival were both 
higher in the chemotherapy arm compared to the whole abdominal radiation arm. There 
were more pelvic failures in the group receiving chemotherapy compared to those treated 
with WAI (18% vs. 13%). Others have similarly reported high pelvic failure rate with 
chemotherapy alone (Mundt et al. 2001; Klopp et al. 2009; Barrena Medel et al. 2011). These 
data lend support to the use of combined modality therapy in the treatment of patients with 
advanced stage endometrial cancer. Several studies have shown improved outcomes with 
combination of radiation and chemotherapy (Schorge et al. 1996; Onda et al. 1997; Hoskins 
et al. 2001; Bruzzone et al. 2004) and it is currently being further evaluated on a Gynecologic 
Oncology Group  study (GOG 258: A Randomized Phase III trial of Cisplatin and Tumor 
Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and 
Paclitaxel for Optimally Debulked Advanced Endometrial Carcinoma). 
3.2.3.3 Role of chemotherapy 
In advanced stage endometrial cancer, chemotherapy may be administered in various 
settings: as primary systemic therapy, adjuvant therapy, or neoadjuvant therapy. Response 
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rates have been over 20% in phase II studies with anthracyclines, platinum compounds, 
alkylating agents, and taxanes (Humber et al. 2007). The Gynecologic Oncology Group has 
undertaken several trials over the last three decades to evaluate the effectiveness of various 
single agents and combinations in the treatment of advanced/recurrent endometrial cancer 
(Table 7). 
Thigpen et al evaluated those patients with advanced stage (stages III/IV) and recurrent 
endometrial cancer who were chemonaive and had measurable disease after prior surgery 
or radiotherapy  on GOG 107(Thigpen et al. 2004). A total of 281 patients were eligible. 
Patients were randomized to receive either doxorubicin alone or a combination of 
doxorubicin and cisplatin. The overall response rate was significantly higher in the 
combination arm compared to the doxorubicin alone arm (42% vs. 25%, p=0.004). The 
median progression free survival was also significantly longer in patients receiving 
doxorubicin plus cisplatin compared to those who received doxorubicin alone (5.7 months 
vs. 3.8 months; HR: 0.74 CI: 0.58-0.94). The toxicity was significantly greater in patients 
treated with the doxorubicin and cisplatin doublet. 
Randall et al included patients with stage III/IV endometrial cancer on GOG 122 (Randall et 
al. 2006). All patients underwent an optimal cytoreduction (residual disease ≤ 2 cm). Patients 
were then randomized to either whole abdominal irradiation (WAI) or chemotherapy with 
cisplatin and doxorubicin (AP). Between 1992 and 2000, 422 patients were accrued. The 
median follow up was 74 months. The 5-year PFS was 50% in the AP arm and 38% in the 
WAI arm (HR: 0.71 CI: 0.55-0.91, p<0.01). The 5-year overall survival was 55% in the AP arm 
and 42% in the WAI arm (HR: 0.68 CI: 0.52-0.89, p<0.01). Analysis of the site of recurrence 
revealed 18% pelvic, 14% abdominal, and 18% extra-abdominal recurrence in the AP arm, 
and 13% pelvic, 16% abdominal, and 22% extra-abdominal recurrence in the WAI arm. 
Administration of AP was associated with significantly more acute toxicity (treatment 
related deaths 4% in AP arm and 2% in the WAI arm). 
Homesley et al compared outcomes between stage III/IV endometrial cancer patients 
treated with combination of cisplatin plus doxorubicin (AP) or cisplatin plus doxorubicin 
plus taxol (TAP)(Homesley et al. 2009). All patients had previously undergone a 
cytoreductive surgery followed by tumor volume directed radiation. The 3-year PFS was not 
significantly different between the two groups (64% vs. 62%; HR: 0.90, CI: 0.69-1.17). 
Subgroup analysis revealed a significant reduction in the risk of recurrence and death 
among patients with gross residual disease treated with TAP compared to AP (RR: 0.50, CI: 
0.27-0.92). Toxicity was also more frequent and more severe in the TAP arm (p<0.01). 
Similarly, both median progression free survival (8.3 months vs. 5.3 months; HR: 0.60, CI: 
0.46-0.78) and median overall survival (15.3 months vs. 12.3 months; HR: 0.75, CI: 0.57-0.99) 
were found to be significantly longer in another GOG study among  advanced stage patients 
treated with (TAP) compared to those treated with (AP) (Fleming et al. 2004). Neurotoxicity 
was worse in the TAP arm compared to the AP arm (40% vs. 5%) and there were 5 treatment 
related deaths in the TAP arm and none in the AP arm. 
The combination of carboplatin and taxol has shown efficacy in phase II setting for the 
primary treatment of advanced and recurrence endometrial cancer (Hoskins et al. 2001). The 
3-year overall survival was 39% and toxicity was acceptable.  Many practitioners are already 
administering this combination despite the lack of evidence from a randomized controlled 
trial. GOG 209 randomized patients with measurable and non-measurable stage III/IV or 
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recurrent endometrial cancer to either TAP or carboplatin/Taxol. This trial has finished 
accrual and its results will be crucial in regards to identifying the most efficacious and safe 
chemotherapy regimen for treatment of patients with high-risk or advanced endometrial 
cancer. This combination is also being evaluated in 2 other ongoing GOG trials (GOG 249 
and GOG 258, described elsewhere). 
 
 
1: Statistically significant; 2: 3-yr PFS 
R: Recurrent; Sx: Surgery; XRT: Radiotherapy; A: Doxorubicin; AP: Doxorubicin + Cisplatin; TAP: 
Paclitaxel + Doxorubicin + Cisplatin;  
GOG: Gynecologic Oncology Group. 
Table 7. Randomized Controlled Trials of Adjuvant Chemotherapy in Advanced 
Endometrial Cancer. 
The role of hormonal treatment in advanced endometrial cancer is discussed with recurrent 
endometrial cancer. 
3.3 Papillary serous and clear cell carcinoma 
Patients diagnosed with these histotypes should undergo comprehensive surgical staging. 
In a study by Thomas et al, 52% of patients with clear cell cancer confined to the uterus on 
clinical assessment  were found to have extrauterine disease on surgical staging (Thomas et 
al. 2008).  In another study by Goff et al, high incidence of lymph node metastasis and 
intraperitoneal metastasis was noted in patients with papillary serous cancer even in the 
absence of high risk features found significant on GOG 33 (Goff et al. 1994).  
Surgical staging should include peritoneal cytology, total abdominal hysterectomy, bilateral 
salpingo-oophorectomy, pelvic and para-aortic lymphadenectomy, omentectomy, and 
biopsies of peritoneal surfaces including the underside of diaphragm(NCCN Clinical 
Practice Guidelines in Oncology (NCCN Guidelines™) for Uterine Neoplasms V.2.2011. © 
2011 National Comprehensive Cancer Network). This is due to the  propensity for omental 
involvement(Sherman et al. 1992; Saygili et al. 2001) and spread to the peritoneal surfaces 
(Geisler et al. 1999; Chan et al. 2003) in women diagnosed with papillary serous or clear cell 
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endometrial cancer.  Maximum cytoreductive effort is recommended in the presence of  
extrauterine disease due to the associated survival advantage(Olawaiye and Boruta 2009). 
The majority of patients with papillary serous or clear cell cancer relapse outside of pelvis, 
and distant recurrences are common even in patients with early stage disease. As a result, 
adjuvant chemotherapy with or without tumor volume directed radiotherapy is widely 
recommended in all patients, even those in whom the disease is confined to the uterus at the 
time of diagnosis(NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for 
Uterine Neoplasms V.2.2011. © 2011 National Comprehensive Cancer Network).  
3.4 Recurrent endometrial cancer 
The risk of endometrial cancer recurrence ranges from  2-15% in early stage disease and 50-
60% in advanced stages or aggressive histologies (Salani et al. 2011). The treatment options 
depend on previous radiation exposure, location and extent of disease, and goals of therapy 
(curative vs. palliative). 
Isolated vaginal recurrence may be treated with surgery, radiotherapy, or a combination 
of both. For unresectable or disseminated metastases, systemic treatment with hormone 
therapy, chemotherapy with or without  tumor directed radiation is generally employed. 
Local/regional recurrence can be treated with radiation ± surgical resection in patients 
with no prior radiation exposure. In the event of prior RT administration, surgical 
exploration,  chemotherapy, or hormonal therapy is preferred (NCCN Clinical Practice 
Guidelines in Oncology (NCCN Guidelines™) for Uterine Neoplasms V.2.2011. © 2011 
National Comprehensive Cancer Network). An analysis of survival after relapse in 
patients included in the PORTEC-trial, revealed 3-year survival rates of 73% after vaginal 
relapse, 8% after pelvic relapse, and 14% after distant relapse. There was no significant 
difference in survival between patients with pelvic and distant relapse (Creutzberg et al. 
2003). 
Historically, total pelvic exenteration has been performed in select patients who have 
failed the standard surgery and radiation treatment  with  reported long term survival 
rates of 20-45% and complication rates of 60-80% (Morris et al. 1996; Barakat et al. 1999). 
For patients who are not candidates for pelvic exenteration, the existing options are not 
very effective. In order to enhance the response to salvage therapies; the role of 
cytoreductive surgery has been explored. Scarabelli et al reported a complete macroscopic 
resection of disease in 65% patients with recurrent endometrial cancer, with significant 
improvement in survival (p<0.01)(Scarabelli et al. 1998). In another series by Bristow et al, 
61 patients with recurrent endometrial cancer were evaluated (Bristow et al. 2006). The 
median post recurrence survival was significantly longer in the optimally cytoreduced 
patients compared to those left with gross residual disease (39 months vs. 14 months, 
p=0.0005). Similar results have been reported by others (Campagnutta et al. 2004; Awtrey 
et al. 2006). 
Hormonal agents have been found valuable in patients with advanced/recurrent disease. 
They are generally associated with fewer side effects (compared to systemic chemotherapy) 
making them particularly suitable for use in patients with poor performance status and/or 
multiple co-morbidities. Various hormonal agents have been used (progestins, selective 
estrogen receptor modulators, aromatase inhibitors,  synthetic steroid derivatives, and 
gonadotropin-releasing (GN-RH) hormone analogs) with a response rate of 9% to 55% in 
different studies(Kokka et al. 2010).  Cochrane Database Systematic Review of hormonal 
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therapy in advanced or recurrent endometrial cancer assessed  542 patients from 6 different 
randomized trials(Stolyarova I ; Rendina et al. 1984; Ayoub et al. 1988; Urbanski et al. 1993; 
Thigpen et al. 1999; Pandya et al. 2001) (Table 8). The results indicated that hormonal 
therapy did not prolong overall survival or progression free survival in women with 
advanced or recurrent endometrial cancer (Kokka et al. 2010). Low-dose hormonal therapy 
was more effective than high-dose hormonal therapy (Thigpen et al. 1999). Despite the lack 
of survival advantage, hormonal agents may be used to alleviate symptoms and prevent 
progression. 
 
 
 
1: Sub-group analysis; 2: Risk of recurrence 
R: Recurrent 
TMX: Tamoxifen; MPA:Medroxyprogesterone Acetate; CAF: Cyclophosphamide + Adriamycin + 5-
Fluorouracil; XRT: Radiotherapy; OPC : 17-Oxyprogesterone Caproate. 
Table 8. Randomized Controlled Trials of Adjuvant Hormonal Therapy in Advanced 
Endometrial Cancer. 
4. Post treatment surveillance 
The current NCCN guidelines recommend physical examination every 3-6 months for 2 
years and then 6 months or annually thereafter(NCCN Clinical Practice Guidelines in 
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Oncology (NCCN Guidelines™) for Uterine Neoplasms V.2.2011. © 2011 National 
Comprehensive Cancer Network).  A review of symptoms and physical examination is 
recommended at each visit. The yield of vaginal cytology (0-7%)  and CXR (0-20%)for 
detection of recurrence has been shown to be very low in asymptomatic patients and 
therefore not currently recommended for routine use(Salani et al. 2011). Although, 
monitoring  CA-125 levels  may be beneficial in select patients  (advanced stage disease, 
serous histology, pretreatment elevated  CA-125); its routine use is also not supported by the 
available evidence (Salani et al. 2011).  
5. Prognosis 
The data concerning survival are provided in the Annual Report on the Results of Treatment 
in Gynecological Cancer (Creasman et al. 2006)and are shown in Table 9. 
 
Strata                  Patients                   1-Year  OS                        3-Year OS                5-Year OS    
Stage IA              1,054                          98.2%                               95.3%                        90.8% 
Stage IB               2,833                          98.7%                               94.6%                        91.1% 
Stage IC              1,426                           97.5%                               89.7%                        85.4% 
Stage IIA              430                            95.2%                               89.0%                        83.3% 
Stage IIB               543                            93.5%                               80.3%                        74.2% 
Stage IIIA             612                            89.0%                               73.3%                        66.2% 
Stage IIIB               80                             73.5%                               56.7%                        49.9% 
Stage IIIC              356                            89.9%                              66.3%                         57.3%  
Stage IVA              49                             63.4%                               34.4%                        25.5% 
Stage IVB              206                            59.5%                               29.0%                        20.1% 
Data taken from Creasman et al, 2006. 
Table 9. Carcinoma of the Corpus Uteri: Patients Treated from 1999-2001; Survival Rates by 
FIGO Surgical Stage. 
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